Skip to content

Study · Randomized controlled trial · 2007

14 results

Teriparatide in postmenopausal women with osteoporosis and mild or moderate renal impairment.

Miller PD, Schwartz EN, Chen P, Misurski DA, Krege JH

Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA30 Sept 2006Cited by 162 (Europe PMC)

PMID17013567 (opens in a new tab)DOI10.1007/s00198-006-0189-8 (opens in a new tab)PepBankPUB-17013567
Publisher pagePubMedAsk about this study
Jump to 14 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study14

11 results from studies that gave the peptide. 11 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In women with osteoporosis, teriparatide increased PINP versus placebo in each renal function subgroup, without significant subgroup interaction.

    In plain wordsTeriparatide increased PINP versus placebo across renal function subgroups in women with osteoporosis.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    IncreasePINP
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    20 or 40 mcg/day · subcutaneousAs given in this study (human).

    Source sentences

    Summary
    Compared with placebo, teriparatide significantly increased PINP and lumbar spine and femoral neck BMD within each renal function subgroup, and there was no evidence that these increases were altered by renal insufficiency (each treatment-by-subgroup interaction p>0.05).
    2 context sentences
    Summary · context
    Using data from the Fracture Prevention Trial, the safety and efficacy of teriparatide [rhPTH(1-34)] in postmenopausal women with osteoporosis and renal impairment were explored.
    Summary · context
    Patients were required to have serum creatinine concentrations < or =2.0 mg/dl and normal serum parathyroid hormone (PTH) concentrations and were randomized to receive daily subcutaneous injections of placebo or teriparatide 20 or 40 mcg/day.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In women with osteoporosis, teriparatide increased lumbar spine BMD versus placebo in each renal subgroup, without significant subgroup interaction.

    In plain wordsTeriparatide increased spine bone density versus placebo across renal function subgroups.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    IncreaseLumbar spine BMD
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    20 or 40 mcg/day · subcutaneousAs given in this study (human).

    Source sentences

    Summary
    Compared with placebo, teriparatide significantly increased PINP and lumbar spine and femoral neck BMD within each renal function subgroup, and there was no evidence that these increases were altered by renal insufficiency (each treatment-by-subgroup interaction p>0.05).
    2 context sentences
    Summary · context
    Using data from the Fracture Prevention Trial, the safety and efficacy of teriparatide [rhPTH(1-34)] in postmenopausal women with osteoporosis and renal impairment were explored.
    Summary · context
    Patients were required to have serum creatinine concentrations < or =2.0 mg/dl and normal serum parathyroid hormone (PTH) concentrations and were randomized to receive daily subcutaneous injections of placebo or teriparatide 20 or 40 mcg/day.
  3. 03HumanRandomized controlled trialEfficacy outcome

    In women with osteoporosis, teriparatide increased femoral neck BMD versus placebo in each renal subgroup, without significant subgroup interaction.

    In plain wordsTeriparatide increased femoral neck bone density versus placebo across renal function subgroups.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    IncreaseFemoral neck BMD
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    20 or 40 mcg/day · subcutaneousAs given in this study (human).

    Source sentences

    Summary
    Compared with placebo, teriparatide significantly increased PINP and lumbar spine and femoral neck BMD within each renal function subgroup, and there was no evidence that these increases were altered by renal insufficiency (each treatment-by-subgroup interaction p>0.05).
    2 context sentences
    Summary · context
    Using data from the Fracture Prevention Trial, the safety and efficacy of teriparatide [rhPTH(1-34)] in postmenopausal women with osteoporosis and renal impairment were explored.
    Summary · context
    Patients were required to have serum creatinine concentrations < or =2.0 mg/dl and normal serum parathyroid hormone (PTH) concentrations and were randomized to receive daily subcutaneous injections of placebo or teriparatide 20 or 40 mcg/day.
  4. 04HumanRandomized controlled trialSafety outcome

    Treatment-emergent adverse event incidences were consistent across treatment assignments within renal function subgroups.

    In plain wordsTeriparatide and comparison groups had consistent adverse event rates within kidney function subgroups.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    No significant changeTreatment-emergent adverse events
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Adverse events · Whole body
    Studied dose
    20 or 40 mcg/day · subcutaneousAs given in this study (human).

    Source sentences

    Summary
    The incidences of treatment-emergent and renal-related adverse events were consistent across treatment assignment in the normal, mildly impaired, and moderately impaired renal function subgroups.
    2 context sentences
    Summary · context
    Using data from the Fracture Prevention Trial, the safety and efficacy of teriparatide [rhPTH(1-34)] in postmenopausal women with osteoporosis and renal impairment were explored.
    Summary · context
    Patients were required to have serum creatinine concentrations < or =2.0 mg/dl and normal serum parathyroid hormone (PTH) concentrations and were randomized to receive daily subcutaneous injections of placebo or teriparatide 20 or 40 mcg/day.
  5. 05HumanRandomized controlled trialSafety outcome

    Renal-related adverse event incidences were consistent across treatment assignments within renal function subgroups.

    In plain wordsTeriparatide and comparison groups had consistent kidney-related adverse event rates within kidney function subgroups.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    No significant changeRenal-related adverse events
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Adverse events · Kidney and urinary
    Studied dose
    20 or 40 mcg/day · subcutaneousAs given in this study (human).

    Source sentences

    Summary
    The incidences of treatment-emergent and renal-related adverse events were consistent across treatment assignment in the normal, mildly impaired, and moderately impaired renal function subgroups.
    2 context sentences
    Summary · context
    Using data from the Fracture Prevention Trial, the safety and efficacy of teriparatide [rhPTH(1-34)] in postmenopausal women with osteoporosis and renal impairment were explored.
    Summary · context
    Patients were required to have serum creatinine concentrations < or =2.0 mg/dl and normal serum parathyroid hormone (PTH) concentrations and were randomized to receive daily subcutaneous injections of placebo or teriparatide 20 or 40 mcg/day.
  6. 06HumanRandomized controlled trialSafety outcome

    Teriparatide increased the incidence of postdose serum calcium above 10.6 mg/dl versus placebo across renal categories.

    In plain wordsTeriparatide increased high postdose blood calcium versus placebo across kidney function groups.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    IncreasePostdose calcium above upper normal limit
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Adverse events · Endocrine and hormones
    Studied dose
    20 or 40 mcg/day · subcutaneousAs given in this study (human).

    Source sentences

    Summary
    Patients in all renal function categories treated with teriparatide 20 or 40 mcg had an increased incidence of 4-6-h postdose serum calcium >10.6 mg/dl (the upper limit of normal) versus placebo;
    2 context sentences
    Summary · context
    Using data from the Fracture Prevention Trial, the safety and efficacy of teriparatide [rhPTH(1-34)] in postmenopausal women with osteoporosis and renal impairment were explored.
    Summary · context
    Patients were required to have serum creatinine concentrations < or =2.0 mg/dl and normal serum parathyroid hormone (PTH) concentrations and were randomized to receive daily subcutaneous injections of placebo or teriparatide 20 or 40 mcg/day.
  7. 07HumanRandomized controlled trialSafety outcome

    Teriparatide 20 mcg/day did not significantly increase calcium above 11 mg/dl at 4-6 hours after dosing versus placebo across renal categories.

    In plain wordsTeriparatide 20 mcg/day did not significantly increase blood calcium above 11 mg/dl versus placebo across kidney function groups.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    No significant changePostdose calcium above 11 mg/dl
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Adverse events · Endocrine and hormones
    Studied dose
    20 mcg/day · subcutaneousAs given in this study (human).

    Source sentences

    Summary
    however, teriparatide 20 mcg/day was not associated with significantly increased incidence of 4-6-h postdose serum calcium >11 mg/dl in any renal function category.
    2 context sentences
    Summary · context
    Patients were required to have serum creatinine concentrations < or =2.0 mg/dl and normal serum parathyroid hormone (PTH) concentrations and were randomized to receive daily subcutaneous injections of placebo or teriparatide 20 or 40 mcg/day.
    Summary · context
    Using data from the Fracture Prevention Trial, the safety and efficacy of teriparatide [rhPTH(1-34)] in postmenopausal women with osteoporosis and renal impairment were explored.
  8. 08HumanRandomized controlled trialSafety outcome

    Teriparatide was associated with more elevated uric acid, especially with moderate renal impairment and the higher dose.

    In plain wordsTeriparatide was linked to more high uric acid, especially with moderate kidney impairment and the higher dose.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    IncreaseElevated uric acid
    Study

    n: not reported in source

    Outcome group
    Adverse events · Kidney and urinary
    Studied dose
    20 or 40 mcg/day · subcutaneousAs given in this study (human).

    Source sentences

    Summary
    Teriparatide therapy was associated with increased incidence of elevated uric acid, with the incidences being highest in patients with moderately impaired renal function and in those receiving teriparatide 40 mcg/day.
    2 context sentences
    Summary · context
    Using data from the Fracture Prevention Trial, the safety and efficacy of teriparatide [rhPTH(1-34)] in postmenopausal women with osteoporosis and renal impairment were explored.
    Summary · context
    Patients were required to have serum creatinine concentrations < or =2.0 mg/dl and normal serum parathyroid hormone (PTH) concentrations and were randomized to receive daily subcutaneous injections of placebo or teriparatide 20 or 40 mcg/day.
  9. 09HumanRandomized controlled trialSafety outcome

    Adverse event data did not suggest increased gout incidence with teriparatide across renal function categories.

    In plain wordsThe data did not suggest more gout with teriparatide across kidney function groups.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    No significant changeGout
    Study

    n: not reported in source

    Outcome group
    Adverse events · Musculoskeletal
    Studied dose
    20 or 40 mcg/day · subcutaneousAs given in this study (human).

    Source sentences

    Summary
    Even so, adverse event data did not suggest an increased incidence of gout or arthralgia or of nephrolithiasis events in teriparatide-treated patients with normal, mild, or moderate renal impairment.
    2 context sentences
    Summary · context
    Using data from the Fracture Prevention Trial, the safety and efficacy of teriparatide [rhPTH(1-34)] in postmenopausal women with osteoporosis and renal impairment were explored.
    Summary · context
    Patients were required to have serum creatinine concentrations < or =2.0 mg/dl and normal serum parathyroid hormone (PTH) concentrations and were randomized to receive daily subcutaneous injections of placebo or teriparatide 20 or 40 mcg/day.
  10. 10HumanRandomized controlled trialSafety outcome

    Adverse event data did not suggest increased arthralgia incidence with teriparatide across renal function categories.

    In plain wordsThe data did not suggest more joint pain with teriparatide across kidney function groups.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    No significant changeArthralgia
    Study

    n: not reported in source

    Outcome group
    Adverse events · Musculoskeletal
    Studied dose
    20 or 40 mcg/day · subcutaneousAs given in this study (human).

    Source sentences

    Summary
    Even so, adverse event data did not suggest an increased incidence of gout or arthralgia or of nephrolithiasis events in teriparatide-treated patients with normal, mild, or moderate renal impairment.
    2 context sentences
    Summary · context
    Using data from the Fracture Prevention Trial, the safety and efficacy of teriparatide [rhPTH(1-34)] in postmenopausal women with osteoporosis and renal impairment were explored.
    Summary · context
    Patients were required to have serum creatinine concentrations < or =2.0 mg/dl and normal serum parathyroid hormone (PTH) concentrations and were randomized to receive daily subcutaneous injections of placebo or teriparatide 20 or 40 mcg/day.
  11. 11HumanRandomized controlled trialSafety outcome

    Adverse event data did not suggest increased nephrolithiasis incidence with teriparatide across renal function categories.

    In plain wordsThe data did not suggest more kidney stones with teriparatide across kidney function groups.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    No significant changeNephrolithiasis
    Study

    n: not reported in source

    Outcome group
    Adverse events · Kidney and urinary
    Studied dose
    20 or 40 mcg/day · subcutaneousAs given in this study (human).

    Source sentences

    Summary
    Even so, adverse event data did not suggest an increased incidence of gout or arthralgia or of nephrolithiasis events in teriparatide-treated patients with normal, mild, or moderate renal impairment.
    2 context sentences
    Summary · context
    Using data from the Fracture Prevention Trial, the safety and efficacy of teriparatide [rhPTH(1-34)] in postmenopausal women with osteoporosis and renal impairment were explored.
    Summary · context
    Patients were required to have serum creatinine concentrations < or =2.0 mg/dl and normal serum parathyroid hormone (PTH) concentrations and were randomized to receive daily subcutaneous injections of placebo or teriparatide 20 or 40 mcg/day.

Studies that did not test the peptide alone3

In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Teriparatide (PTH 1-34).

  1. 12HumanNot a test of Teriparatide (PTH 1-34) aloneObservational studyEfficacy outcome

    Teriparatide-associated vertebral fracture risk reductions did not differ significantly between women with normal and impaired renal function.

    In plain wordsVertebral fracture risk reductions with teriparatide were similar in women with normal and impaired kidney function.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    No significant changeVertebral fracture risk reduction by renal function
    Study

    n: not reported in source

    Comparator
    Normal versus impaired renal function
    Outcome group
    Bone and joint · Musculoskeletal

    Source sentences

    Summary
    Similarly, teriparatide-mediated vertebral and nonvertebral fracture risk reductions were similar and did not differ significantly between patients with normal or impaired renal function (treatment-by-subgroup interactions p>0.05).
    2 context sentences
    Summary · context
    Using data from the Fracture Prevention Trial, the safety and efficacy of teriparatide [rhPTH(1-34)] in postmenopausal women with osteoporosis and renal impairment were explored.
    Summary · context
    Patients were required to have serum creatinine concentrations < or =2.0 mg/dl and normal serum parathyroid hormone (PTH) concentrations and were randomized to receive daily subcutaneous injections of placebo or teriparatide 20 or 40 mcg/day.

    In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).

  2. 13HumanNot a test of Teriparatide (PTH 1-34) aloneObservational studyEfficacy outcome

    Teriparatide-associated nonvertebral fracture risk reductions did not differ significantly between women with normal and impaired renal function.

    In plain wordsNonvertebral fracture risk reductions with teriparatide were similar in women with normal and impaired kidney function.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    No significant changeNonvertebral fracture risk reduction by renal function
    Study

    n: not reported in source

    Comparator
    Normal versus impaired renal function
    Outcome group
    Bone and joint · Musculoskeletal

    Source sentences

    Summary
    Similarly, teriparatide-mediated vertebral and nonvertebral fracture risk reductions were similar and did not differ significantly between patients with normal or impaired renal function (treatment-by-subgroup interactions p>0.05).
    2 context sentences
    Summary · context
    Using data from the Fracture Prevention Trial, the safety and efficacy of teriparatide [rhPTH(1-34)] in postmenopausal women with osteoporosis and renal impairment were explored.
    Summary · context
    Patients were required to have serum creatinine concentrations < or =2.0 mg/dl and normal serum parathyroid hormone (PTH) concentrations and were randomized to receive daily subcutaneous injections of placebo or teriparatide 20 or 40 mcg/day.

    In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).

  3. 14HumanNot a test of Teriparatide (PTH 1-34) aloneObservational studyEfficacy outcome

    Baseline renal function did not significantly modify teriparatide-associated changes in mean GFR.

    In plain wordsChanges in kidney filtration with teriparatide did not differ significantly across baseline kidney function groups.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    No significant changeGFR change by renal function
    Study

    n: not reported in source

    Comparator
    Baseline renal function subgroups
    Outcome group
    Kidney function · Kidney and urinary

    Source sentences

    Summary
    Teriparatide induced changes in mean GFR were unaffected by baseline renal function (treatment-by-renal function interaction p>0.05 for normal, mildly impaired, or moderately impaired subgroups).
    2 context sentences
    Summary · context
    Using data from the Fracture Prevention Trial, the safety and efficacy of teriparatide [rhPTH(1-34)] in postmenopausal women with osteoporosis and renal impairment were explored.
    Summary · context
    Patients were required to have serum creatinine concentrations < or =2.0 mg/dl and normal serum parathyroid hormone (PTH) concentrations and were randomized to receive daily subcutaneous injections of placebo or teriparatide 20 or 40 mcg/day.

    In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:26 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.